Skip to main content
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 1998 Dec 7;11(6):328–335. doi: 10.1002/(SICI)1098-2825(1997)11:6<328::AID-JCLA3>3.0.CO;2-1

Detection of a common mutation in factor V gene responsible for resistance to activated protein C causing predisposition to thrombosis

A Ferreira‐Gonzalez 1,, LM Fisher 1, CM Lehman 1, MH Langley 1, DH Lofland 1, Q Xia 1, NX Nguyen 1, D Modesto 1, JB Willoughby 1, DS Wilkinson 1, CT Garrett 1
PMCID: PMC6760686  PMID: 9406051

Abstract

Hereditary predisposition to thrombosis due to activated protein C resistance (APCR) has been attributed to a missense mutation in the factor V gene at nucleotide 1691 (G to A), causing replacement of arginine at codon 506 with glutamine. Using an RFLP‐PCR assay to detect this mutation, we measured a prevalence of 3.3% in healthy Caucasians and 1.25% in healthy African‐Americans. In addition, we evaluated a total of 90 consecutive specimens submitted to the coagulation laboratory at the Medical College of Virginia for the presence of this mutation. We compared our results for 78 of these specimens with the values measured by a modified partial thromboplastin assay, the COATEST. Twelve of the 90 samples could not be tested using the COATEST because the patients were undergoing anticoagulant therapy. One of the latter 12 specimens was positive by the RFLP‐PCR test. Using the genetic test as the definitive assay and the cutoff value established for distinguishing between normal and abnormal results by the COATEST, the COATEST had a sensitivity of 50% and specificity of 93% for the detection of factor V mutation. Analysis of the 90 samples stratified by ethnic groups revealed a frequency of mutation of 13.3% for Caucasians and 6.88% for African‐Americans, although with the present sample size, the difference was not statistically significant. Although the COATEST is technically simpler to perform than the genetic test for diagnosing the presence of the factor V mutation, its use for this purpose is limited due to low sensitivity. Thus where this disorder is clinically suspected, submission of the specimen directly for genetic testing by RFLP‐PCR or equivalent assay should be considered. J. Clin. Lab. Anal. 11:328–335, 1997. © 1997 Wiley‐Liss, Inc.

Keywords: hereditary activated protein C resistance, RFLP‐PCR, hereditary thrombosis, APCR

References

  • 1. Weinmann EE, Salzman EW: Deep‐Vein Thrombosis. N Engl J Med 331: 1630–1641, 1994. [DOI] [PubMed] [Google Scholar]
  • 2. Dahlback B: Molecular genetics of thrombophilia: Factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. J Lab Clin Med 125: 566–571, 1995. [PubMed] [Google Scholar]
  • 3. Dahlback B: Inherited resistance to activated protein C, a major basis of venous thrombosis, is caused by deficient anticoagulant cofactor function of factor V. Haematologica 80: (2 Suppl): 102–113, 1995. [PubMed] [Google Scholar]
  • 4. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlback B: Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 85: 3518–3523, 1995. [PubMed] [Google Scholar]
  • 5. Dahlback B: Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. J Intern Med 237: 221–227, 1995. [DOI] [PubMed] [Google Scholar]
  • 6. Zoller B, Svensson PJ, He X, Dahlback B: Identification of the same factor V gene mutation in 47 out of 50 thrombosis‐prone families with inherited resistance to activated protein C. J Clin Invest 94: 2521–2524, 1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Dahlback B: Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 24: 139–151, 1994. [DOI] [PubMed] [Google Scholar]
  • 8. Bertina RM, Koeleman BP, Koster T, Resendaal FR, Dirven RJ, de Ronde H, Van der Velder PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64–67, 1994. [DOI] [PubMed] [Google Scholar]
  • 9. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB: The mechanism of inactivation of human platelet factor Va from normal and activated protein C‐resistant individuals. J Biol Chem 270: 20794–20800, 1995. [DOI] [PubMed] [Google Scholar]
  • 10. de Maat MP, Kluft C, Jesperson J, Gram J: World distribution of factor V FV R506Q Leiden. Lancet 347: 58, 1996. [PubMed] [Google Scholar]
  • 11. Schroder W, Koessling M, Wulff K, Wehnert M, Herrmann FH: World distribution of factor V FV R506Q Leiden. Lancet 347: 58–59, 1996. [PubMed] [Google Scholar]
  • 12. Fouere S, Guibal F, Morel P: World distribution of factor V FV R506Q Leiden. Lancet 347: 59, 1996. [PubMed] [Google Scholar]
  • 13. Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 346: 1133–1134, 1995. [DOI] [PubMed] [Google Scholar]
  • 14. Rosen S, Johansson K, Lindberg K, Dahlback B: Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals: The APC Resistance Study Group. Thromb Haemost 72: 255–260, 1994. [PubMed] [Google Scholar]
  • 15. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR: High prevalence of a mutation in the factor V gene within the U.K. population: Relationship to activated protein C resistance and familial thrombosis. Br J Haematol 88: 219–222, 1994. [DOI] [PubMed] [Google Scholar]
  • 16. Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330: 517–522, 1994. [DOI] [PubMed] [Google Scholar]
  • 17. Liu XY, Nelson D, Grant C, Morthland V, Goodnight SH, Press RD: Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C. Diagn Mol Pathol 4: 191–197, 1995. [DOI] [PubMed] [Google Scholar]
  • 18. Arruda VR, Annichino‐Bizzacchi JM, Costa FF, Reitsma PH: Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol 49: 242–243, 1995. [DOI] [PubMed] [Google Scholar]
  • 19. Ma DD, Aboud MR, Williams BG, Isbister JP: Activated protein C resistance (APC) and inherited factor V (FV) mis‐sense mutation in patients with venous and arterial thrombosis in a haematology clinic. Aust N Z J Med 25: 151–154, 1995. [DOI] [PubMed] [Google Scholar]
  • 20. Kambayashi J, Fujimura H, Kawasaki T, Sakon M, Monden M, Suehisa E, Amino N: The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka. Thromb Res 79: 227–229, 1995. [DOI] [PubMed] [Google Scholar]
  • 21. Gou D, Naipal A, Reitsma PH: World distribution of factor V FV R506Q Leiden. Lancet 347: 59, 1996. [PubMed] [Google Scholar]
  • 22. Pottinger P, Sigurdsson F, Berliner N: Detection of the Factor V FV R506Q Leiden in a non‐selected black population. Blood 87: 2091, 1996. [PubMed] [Google Scholar]
  • 23. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332: 912–917, 1995. [DOI] [PubMed] [Google Scholar]
  • 24. Dahlback B: Molecular genetics of venous thromboembolism: Ann Med 27: 187–192, 1995. [DOI] [PubMed] [Google Scholar]
  • 25. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85: 1504–1508, 1995. [PubMed] [Google Scholar]
  • 26. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, Ten Cate JW, Mertens K, Van Moutik JA: Association of idiopathic venous thromboembolism with single point‐mutation at arg 506 of Factor V. Lancet 343: 1535–1536, 1994. [DOI] [PubMed] [Google Scholar]
  • 27. Dhote R, Bachmeyer C, Horellou MH, Toulon P, Christoforov B: Central retinal vein thrombosis associated with resistance to activated protein C. Am J Ophthalmol 120: 388–389, 1995. [DOI] [PubMed] [Google Scholar]
  • 28. Petaja J, Jalanko H, Homberg C, Kinnunen S, Syrjala M: Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing nephrotic syndrome. J Pediatr 127: 103–105, 1995. [DOI] [PubMed] [Google Scholar]
  • 29. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 173: 210–213, 1995. [DOI] [PubMed] [Google Scholar]
  • 30. Osterud B, Robertsen R, Asvang GB, Thijssen F: Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinolysis 5: 853–854, 1994. [DOI] [PubMed] [Google Scholar]
  • 31. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR: Increased risk of venous thrombosis in oral‐contraceptive users who are carriers of factor V FV R506Q Leiden mutation. Lancet 344: 1453–1457, 1994. [DOI] [PubMed] [Google Scholar]
  • 32. Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A: Ischemic stroke in young patients with Activated Protein C Resistance: A report of three cases belonging to three different kindreds. Stroke 26: 885–890, 1995. [DOI] [PubMed] [Google Scholar]
  • 33. Demarmels‐Biasiutti F, Merlo C, Furlan M, Suzler I, Binder BR, Lammle B: No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis 6: 456–459, 1995. [DOI] [PubMed] [Google Scholar]
  • 34. Prohaska W, Mannebach H, Schmidt M, Gleichmann U, Kleesiek K: Evidence against heterozygous coagulation factor V 1691 G→A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. J Mol Med 73: 521–524, 1995. [DOI] [PubMed] [Google Scholar]
  • 35. Press RD, Liu XY, Beamer N, Coull BM. Ischemic stroke in the elderly: Role of the common factor V mutation causing resistance to activated protein C. Stroke 27: 44–48, 1996. [DOI] [PubMed] [Google Scholar]
  • 36. Machotka SV, Garrett CT, Schwartz AM, Callahan R: Amplification of the proto‐oncogenes int‐2, c‐erb‐2 and c‐myc in human breast cancer. Clin Chim Acta 184: 207–217, 1989. [DOI] [PubMed] [Google Scholar]
  • 37. Ferreira‐Gonzalez A, DeAngelo AB, Nasim S, Garrett CT: Ras oncogene activation during hepatocarcinogenesis in B6C3F1 male mice by dichloroacetic and trichloroacetic acids. Carcinogenesis 16: 495–500, 1995. [DOI] [PubMed] [Google Scholar]
  • 38. Le DT, Griffin JH, Greengard JS, Mujundar V, Rapaport SI: Use of a generally applicable tissue factor‐dependent factor V assay to detect activated protein C‐resistant Factor Va in patients receiving warfarin and in patients with lupus anticoagulant. Blood 85: 1704–1711, 1995. [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES